Kairos Pharma, Ltd.
KAPA
$0.8133
$0.02833.61%
AMEX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 245.26% | 132.08% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 277.55% | 72.52% | |||
| Operating Income | -277.55% | -72.52% | |||
| Income Before Tax | 6.40% | -313.83% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 6.40% | -313.83% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 6.40% | -313.83% | |||
| EBIT | -277.55% | -72.52% | |||
| EBITDA | -309.91% | -88.46% | |||
| EPS Basic | 23.75% | -300.00% | |||
| Normalized Basic EPS | -22.83% | -300.00% | |||
| EPS Diluted | 23.75% | -300.00% | |||
| Normalized Diluted EPS | -22.83% | -300.00% | |||
| Average Basic Shares Outstanding | 22.70% | 3.29% | |||
| Average Diluted Shares Outstanding | 22.70% | 3.29% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||